Literature DB >> 22889062

Inhibition of Yersinia pestis DNA adenine methyltransferase in vitro by a stibonic acid compound: identification of a potential novel class of antimicrobial agents.

J C McKelvie1, M I Richards, J E Harmer, T S Milne, P L Roach, P C F Oyston.   

Abstract

BACKGROUND AND
PURPOSE: Multiple antibiotic resistant strains of plague are emerging, driving a need for the development of novel antibiotics effective against Yersinia pestis. DNA adenine methylation regulates numerous fundamental processes in bacteria and alteration of DNA adenine methlytransferase (Dam) expression is attenuating for several pathogens, including Y. pestis. The lack of a functionally similar enzyme in humans makes Dam a suitable target for development of novel therapeutics for plague. EXPERIMENTAL APPROACH: Compounds were evaluated for their ability to inhibit Dam activity in a high-throughput screening assay. DNA was isolated from Yersinia grown in the presence of lead compounds and restricted to determine the effect of inhibitors on DNA methylation. Transcriptional analysis was undertaken to determine the effect of an active inhibitor on virulence-associated phenotypes. KEY
RESULTS: We have identified a series of aryl stibonic acids which inhibit Dam in vitro. The most active, 4-stibonobenzenesulfonic acid, exhibited a competitive mode of inhibition with respect to DNA and a K(i) of 6.46 nM. One compound was found to inhibit DNA methylation in cultured Y. pestis. The effects of this inhibition on the physiology of the cell were widespread, and included altered expression of known virulence traits, including iron acquisition and Type III secretion. CONCLUSIONS AND IMPLICATIONS: We have identified a novel class of potent Dam inhibitors. Treatment of bacterial cell cultures with these inhibitors resulted in a decrease in DNA methylation. Expression of virulence factors was affected, suggesting these inhibitors may attenuate bacterial infectivity and function as antibiotics.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22889062      PMCID: PMC3570013          DOI: 10.1111/j.1476-5381.2012.02134.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  DNA adenine methylase mutants of Salmonella typhimurium show defects in protein secretion, cell invasion, and M cell cytotoxicity.

Authors:  F García-Del Portillo; M G Pucciarelli; J Casadesús
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  DNA adenine methylase is essential for viability and plays a role in the pathogenesis of Yersinia pseudotuberculosis and Vibrio cholerae.

Authors:  S M Julio; D M Heithoff; D Provenzano; K E Klose; R L Sinsheimer; D A Low; M J Mahan
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

3.  An essential role for DNA adenine methylation in bacterial virulence.

Authors:  D M Heithoff; R L Sinsheimer; D A Low; M J Mahan
Journal:  Science       Date:  1999-05-07       Impact factor: 47.728

4.  Functional characterization of Escherichia coli DNA adenine methyltransferase, a novel target for antibiotics.

Authors:  Neda Mashhoon; Michael Carroll; Cynthia Pruss; Joerg Eberhard; Sawako Ishikawa; R August Estabrook; Norbert Reich
Journal:  J Biol Chem       Date:  2004-09-28       Impact factor: 5.157

5.  Clocks and switches: bacterial gene regulation by DNA adenine methylation.

Authors:  David A Low; Josep Casadesús
Journal:  Curr Opin Microbiol       Date:  2008-04-08       Impact factor: 7.934

6.  A deoxyribonuclease of Diplococcus pneumoniae specific for methylated DNA.

Authors:  S Lacks; B Greenberg
Journal:  J Biol Chem       Date:  1975-06-10       Impact factor: 5.157

7.  Mutations within the catalytic motif of DNA adenine methyltransferase (Dam) of Aeromonas hydrophila cause the virulence of the Dam-overproducing strain to revert to that of the wild-type phenotype.

Authors:  Tatiana E Erova; Amin A Fadl; Jian Sha; Bijay K Khajanchi; Lakshmi L Pillai; Elena V Kozlova; Ashok K Chopra
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

8.  Phase variation of Ag43 in Escherichia coli: Dam-dependent methylation abrogates OxyR binding and OxyR-mediated repression of transcription.

Authors:  W Haagmans; M van der Woude
Journal:  Mol Microbiol       Date:  2000-02       Impact factor: 3.501

9.  Dam methylation controls O-antigen chain length in Salmonella enterica serovar enteritidis by regulating the expression of Wzz protein.

Authors:  Sebastián H Sarnacki; Cristina L Marolda; Mariángeles Noto Llana; Mónica N Giacomodonato; Miguel A Valvano; María Cristina Cerquetti
Journal:  J Bacteriol       Date:  2009-08-28       Impact factor: 3.490

10.  Structure and substrate recognition of the Escherichia coli DNA adenine methyltransferase.

Authors:  John R Horton; Kirsten Liebert; Miklos Bekes; Albert Jeltsch; Xiaodong Cheng
Journal:  J Mol Biol       Date:  2006-02-28       Impact factor: 5.469

View more
  3 in total

1.  A comparative analysis of methylome profiles of Campylobacter jejuni sheep abortion isolate and gastroenteric strains using PacBio data.

Authors:  Kathy T Mou; Usha K Muppirala; Andrew J Severin; Tyson A Clark; Matthew Boitano; Paul J Plummer
Journal:  Front Microbiol       Date:  2015-01-14       Impact factor: 5.640

2.  The methylome of the gut microbiome: disparate Dam methylation patterns in intestinal Bacteroides dorei.

Authors:  Michael T Leonard; Austin G Davis-Richardson; Alexandria N Ardissone; Kaisa M Kemppainen; Jennifer C Drew; Jorma Ilonen; Mikael Knip; Olli Simell; Jorma Toppari; Riitta Veijola; Heikki Hyöty; Eric W Triplett
Journal:  Front Microbiol       Date:  2014-07-17       Impact factor: 5.640

3.  A role for the bacterial GATC methylome in antibiotic stress survival.

Authors:  Nadia R Cohen; Christian A Ross; Saloni Jain; Rebecca S Shapiro; Arnaud Gutierrez; Peter Belenky; Hu Li; James J Collins
Journal:  Nat Genet       Date:  2016-03-21       Impact factor: 38.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.